AtriCure (ATRC): What the Docs are Saying on Surgical LAAC Competition, LeAAPS, and BoxX-NoAF

AtriCure shares are up 115% from early June (vs. SPX +1%, RTY -7%, and IHI +12%) as excitement has built into the readouts for AtriCure's TAM expanding clinical trials, with BoxX-NoAF data slated for 1H27 and LeAAPS within the next few years (depending on how events accrue). With multiple potentially needle-moving catalysts on the horizon, and competition ramping up in surgical left atrial appendage closure (LAAC) following the recent launch of Edwards' Ecliptis, we spoke with cardiac surgeons on innovation in the space, the competitive landscape, and what this all means for AtriCure. Our main takeaways were that: (1) surgeons' views of the competitive landscape in surgical LAAC were quite varied, with some preferring Ecliptis' form factor, others citing no meaningful difference and emphasizing AtriCure's first mover advantage and broader afib ecosystem - in our view, Edwards' pricing/bundling strategy will be a key driver of where share settles out;